Stockscreener 앱 받기
10.31
0.68%
0.07
시간 외 거래:
10.27
-0.04
-0.39%
전일 마감가:
$10.24
열려 있는:
$10.08
하루 거래량:
2.43M
Relative Volume:
2.80
시가총액:
$597.46M
수익:
-
순이익/손실:
$-117.81M
주가수익비율:
16.11
EPS:
0.64
순현금흐름:
$74.30M
1주 성능:
+35.12%
1개월 성능:
+70.98%
6개월 성능:
+160.68%
1년 성능:
+244.82%
1일 변동 폭
$10.08
$12.83
1주일 범위
$7.20
$13.60
52주 변동 폭
$2.612
$13.60
Omeros Corporation Stock (OMER) Company Profile
명칭
Omeros Corporation
전화
206-676-5000
주소
201 ELLIOTT AVENUE WEST, SEATTLE, WA
OMER을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
OMER
Omeros Corporation
|
10.31 | 597.46M | 0 | -117.81M | 74.30M | -1.88 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Omeros Corporation Stock (OMER) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-11-14 | 개시 | Rodman & Renshaw | Buy |
| 2022-12-08 | 다운그레이드 | UBS | Buy → Neutral |
| 2022-11-08 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-06-08 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-10-08 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2021-10-01 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2021-10-01 | 다운그레이드 | Wedbush | Neutral → Underperform |
| 2021-09-27 | 개시 | JP Morgan | Neutral |
| 2021-02-01 | 개시 | UBS | Buy |
| 2020-10-20 | 개시 | BofA Securities | Buy |
| 2020-08-21 | 재확인 | H.C. Wainwright | Buy |
| 2020-08-14 | 재확인 | Maxim Group | Buy |
| 2019-05-06 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-07-12 | 개시 | Seaport Global Securities | Buy |
| 2018-03-23 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2018-03-05 | 다운그레이드 | Needham | Buy → Hold |
| 2017-11-08 | 개시 | H.C. Wainwright | Buy |
| 2017-05-11 | 다운그레이드 | Cantor Fitzgerald | Buy → Neutral |
| 2017-03-17 | 재확인 | Maxim Group | Buy |
| 2017-03-17 | 재확인 | Needham | Buy |
| 2016-11-16 | 재확인 | Wedbush | Outperform |
| 2016-11-10 | 재확인 | Needham | Buy |
| 2016-08-10 | 재확인 | Maxim Group | Buy |
| 2016-06-03 | 개시 | Cantor Fitzgerald | Buy |
| 2016-03-02 | 재확인 | Needham | Buy |
| 2016-02-29 | 재확인 | Wedbush | Outperform |
| 2015-11-11 | 재확인 | Needham | Buy |
| 2015-08-18 | 재확인 | WBB Securities | Strong Buy |
| 2015-08-10 | 개시 | ROTH Capital | Buy |
모두보기
Omeros Corporation 주식(OMER)의 최신 뉴스
Wellington Management Group LLP Invests $305,000 in Omeros Co. (NASDAQ:OMER) - MarketBeat
Needham & Company LLC Reiterates Hold Rating for Omeros (NASDAQ:OMER) - Defense World
Omeros Corporation Announces Positive Results for Narsoplimab in Treating Thrombotic MicroangiopathyOn December 19, 2024, Omeros Corporation (NASDAQ: OMER) revealed the outcomes of a primary statistical analysis involving narsoplimab, the comp - Defense World
Omeros' (OMER) Hold Rating Reaffirmed at Needham & Company LLC - MarketBeat
BNP Paribas Financial Markets Buys 7,016 Shares of Omeros Co. (NASDAQ:OMER) - Defense World
Omeros (NASDAQ:OMER) Reaches New 12-Month HighStill a Buy? - MarketBeat
Stock Of The Day / 12.19.24 / OMER for NASDAQ:OMER by AlexX31 - TradingView
Top Midday Gainers - Marketscreener.com
Omeros jumps as lead drug succeeds in pivotal trial for blood transplant patients - MSN
Omeros Antibody Improves Overall Survival In Rare Complication After Stem Cell Transplant, Stock Surges - Benzinga
Omeros (NASDAQ:OMER) Shares Gap UpShould You Buy? - MarketBeat
Omeros Stock Gains 52% On Successful Trial Results - MarketWatch
Omeros antibody improves overall survival by 68% in rare condition, new analysis finds - Fierce Biotech
Omeros stock soars to 52-week high, hits $12.65 - Investing.com
Omeros Reports Narsoplimab TA-TMA Trial Success; Stock Surges - Yahoo Finance
Omeros stock surges on positive survival data for narsoplimab - Investing.com
Omeros stock jumps after trial outcome (OMER:NASDAQ) - Seeking Alpha
Omeros reports survival benefit with narsoplimab in TA-TMA - Investing.com
Omeros announces narsoplimab trial meets primary endpoint - TipRanks
Omeros’ Narsoplimab Meets its Pivotal Trial Primary Endpoint – Statistical Analysis Shows Survival Superiority Over External Control in Patients with TA-TMA - Business Wire
Omeros (STU:3O8) Operating Income : €-159.24 Mil (TTM As of Sep. 2024) - GuruFocus.com
Omeros (STU:3O8) GF Score : 50/100 (As of Dec. 18, 2024) - GuruFocus.com
Omeros Co. (NASDAQ:OMER) Short Interest Down 16.9% in November - MarketBeat
Omeros Corporation: Investment Opportunity Finely Poised As The Market Waits For Key Updates - Seeking Alpha
Omeros Corporation (OMER) Stock Drops Amid Financial Report Conc - GuruFocus.com
Omeros Corp (OMER): Profit-Taking Time Amid ASH Presentations and Financial Challenges - MSN
Omeros Corporation Announces Presentation of Positive Zaltenibart Data at ASH Annual Meeting - BioSpace
Omeros reports progress on PNH treatment zaltenibart - Investing.com
Omeros reports progress on PNH treatment zaltenibart By Investing.com - Investing.com UK
Omeros (NASDAQ:OMER) Stock Price Up 7.8%What's Next? - MarketBeat
Omeros stock soars to 52-week high, hits $12.55 By Investing.com - Investing.com Australia
Omeros stock soars to 52-week high, hits $12.55 - Investing.com
Omeros Corporation (OMER) Stock Surges Amidst Biotech Sector Gai - GuruFocus.com
Omeros Corp (OMER) Stock Surges Amid Biotech Sector Activity - GuruFocus.com
Omeros Corporation Announces Upcoming Presentations at ASH Annual Meeting - The Bakersfield Californian
(OMER) Trading Advice - Stock Traders Daily
Omeros Corp (OMER) Stock Surges Amidst Biotech Sector Activity - GuruFocus.com
Omeros (NASDAQ:OMER) Hits New 12-Month HighHere's Why - MarketBeat
Omeros Updates Progress on Narsoplimab Biologics License Resubmission; Stock up Over 30% on News - Yahoo Finance
Omeros surges 22% on clarity for BLA resubmission for narsoplimab - MSN
Omeros stock soars to 52-week high, hits $7.53 By Investing.com - Investing.com Australia
Omeros nears resubmission of narsoplimab BLA By Investing.com - Investing.com South Africa
Omeros nears resubmission of narsoplimab BLA - Investing.com India
Omeros stock soars to 52-week high, hits $7.53 - Investing.com
Omeros Corporation Provides Update on Progress Toward BLA Resubmission - Business Wire
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.47% - MSN
StockNews.com Upgrades Omeros (NASDAQ:OMER) to Hold - MarketBeat
Omeros (NASDAQ:OMER) Upgraded at StockNews.com - Defense World
Long Term Trading Analysis for (OMER) - Stock Traders Daily
IgA Nephropathy Drugs Market: Driving Rapid Expansion with - openPR
Omeros Corporation (OMER) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.88%
2.65%
자본화:
|
볼륨(24시간):